PwPepwise

IGF-1 LR3

Muscle & Performance

a.k.a. Long-arg-3 IGF-1

IGF-1 analog with extended half-life

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified form of the naturally occurring insulin-like growth factor-1.

§Dosing at a glance

1 protocol · from the research
What it's forDoseHow oftenHowFor how long
Fetal sheep (continuous into a vein infusion — growth and metabolic research)6.6 µg—IntravenousInjected directly into a vein.1 wks

Approximate values pulled from the research — double-check before dosing.

§01Summary

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified form of the naturally occurring insulin-like growth factor-1, engineered for greater potency and longer duration of action. By carrying a 13-amino-acid N-terminal extension and an arginine substitution, it binds poorly to IGF-binding proteins that normally limit IGF-1's activity, allowing it to engage the IGF-1 receptor more freely and for longer periods. In the body, IGF-1 LR3 activates signaling pathways that support cell growth, protein synthesis, and tissue repair. Preliminary evidence from preclinical models suggests it may support nerve regeneration when delivered locally via controlled-release scaffolds4. Research in fetal animal models has explored its potential to promote growth in growth-restricted settings, though it has not demonstrated significant growth-promoting effects in nutrient-limited conditions such as placental insufficiency2. Importantly, studies in fetal sheep have shown that sustained IGF-1 LR3 exposure may suppress insulin secretion through mechanisms that, with prolonged exposure, appear to involve lasting changes at the level of the insulin-producing cells themselves1,3. Human studies across therapeutic indications are an active and emerging area, with the evidence base continuing to develop.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

IGF-1 LR3 is a synthetic analog of human insulin-like growth factor-1 (IGF-1), distinguished by the addition of a 13-amino-acid N-terminal extension sequence and the substitution of arginine for glutamic acid at position 3. The structural modification at position 3 dramatically reduces binding affinity for IGF-binding proteins (IGFBPs), particularly IGFBP-3, which normally sequesters the majority of circulating IGF-1 in an inactive ternary complex. By evading IGFBP sequestration, IGF-1 LR3 has a substantially longer effective half-life and greater bioavailability at the tissue level compared to native IGF-115.

At the receptor level, IGF-1 LR3 binds and activates the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase. Upon ligand engagement, IGF-1R undergoes autophosphorylation and recruits insulin receptor substrate (IRS) proteins, initiating two principal downstream signaling cascades: the phosphoinositide 3-kinase (PI3K)/AKT pathway, which promotes cell survival, glucose uptake, protein synthesis, and anti-apoptotic signaling; and the Ras/extracellular signal-regulated kinase (ERK/MAPK) pathway, which drives cell proliferation and differentiation5. Both pathways have been identified as mediators of IGF-1-stimulated cardiomyocyte proliferation in fetal sheep models5.

In the context of pancreatic beta-cell biology, IGF-1 LR3 signaling produces dose- and duration-dependent effects on insulin secretion. Acute 90-minute exposure in fetal sheep suppresses in vivo glucose-stimulated insulin secretion by approximately 66% without leaving a detectable intrinsic islet defect3, suggesting an indirect systemic mechanism. Prolonged one-week infusion, however, produces a lasting suppression of insulin secretory capacity that persists in isolated fetal islets ex vivo, indicating that chronic IGF-1R activation can induce a durable intrinsic beta-cell functional change independent of circulating IGF-1 levels1. Pancreatic insulin content remains unchanged under either condition, localizing the defect to secretory machinery rather than insulin biosynthesis or storage1.

In peripheral nerve tissue, local sustained delivery of IGF-1 LR3 appears to promote axonal regeneration, consistent with IGF-1R's established role in neuronal survival and neurite outgrowth via PI3K/AKT and MAPK signaling4. In amino acid metabolism, IGF-1 LR3 infusion in fetal sheep may increase cellular uptake or catabolism of branched-chain amino acids (BCAAs), as reflected by reduced circulating BCAA concentrations in treated animals2, consistent with IGF-1's known role in stimulating amino acid transport and anabolic substrate utilization.

§04Evidence & efficacy

Evidence base
78Studies
28Human
28Animal

IGF-1 LR3 has been investigated across several preclinical indications, with evidence currently limited to animal models.

In the context of peripheral nerve regeneration, a controlled-release IGF-1 LR3 construct incorporated into a novel decellularized plant-based nerve conduit appeared to significantly improve axonal regeneration in a rat sciatic nerve defect model, with outcomes comparable to autologous nerve grafts across gait, electrophysiology, and histological assessments4. This represents a promising but early-stage finding requiring replication in larger studies.

In fetal growth research, one-week continuous IGF-1 LR3 infusion in normal fetal sheep increased fetal weight and elevated IGF-1 signaling, consistent with its anabolic mechanism1. However, in a growth-restricted fetal sheep model reflecting placental insufficiency, IGF-1 LR3 at a lower infusion rate did not improve fetal body weight, insulin concentrations, glucose levels, or glucose-stimulated insulin secretion compared to vehicle2. The authors propose that underlying nutrient and oxygen deficits in the FGR setting may prevent anabolic growth responses, and that IGF-1 LR3 alone may be insufficient as a therapeutic when substrate availability is not addressed2.

Across the metabolic domain, IGF-1 LR3 infusion consistently appears to suppress insulin secretion in vivo in fetal sheep models, with the degree of lasting effect depending on duration of exposure1,3.

Human efficacy data across all investigated indications is an active and emerging area of research.

§05Safety

The safety profile of IGF-1 LR3, as currently understood from preclinical evidence, centers on several biologically meaningful signals identified in animal models.

In fetal sheep receiving continuous IV infusion of IGF-1 LR3 for one week, lower fetal plasma glucose concentrations were observed compared to controls (P=0.0012), indicating a hypoglycemic effect in the fetal compartment1. The same one-week infusion model demonstrated a persistent intrinsic defect in beta-cell insulin secretory capacity, observable in isolated islets even after removal from the IGF-1 LR3 environment1. By contrast, an acute 90-minute infusion produced pronounced in vivo insulin suppression (approximately 66% reduction during hyperglycemic clamp) but did not produce lasting islet-level dysfunction in subsequently isolated islets, suggesting that the duration of exposure is an important determinant of this effect3. In growth-restricted fetal sheep receiving a lower continuous dose, no insulin suppression was observed, and no explicit adverse events were reported, though a notable reduction in circulating branched-chain amino acids was observed in the treatment group2.

In a rat sciatic nerve regeneration model, no systemic toxicity was reported with local controlled-release IGF-1 LR3 delivery, and local biocompatibility appeared acceptable on histological assessment4.

No human safety data from clinical trials is available in the current evidence base; human tolerability, long-term safety, and interaction profiles are being investigated as clinical research advances.

§06History

IGF-1 LR3 was developed in the early 1990s as a research tool designed to overcome a key limitation of native IGF-1: its rapid sequestration by IGF-binding proteins in circulation. The foundational work characterizing the structural rationale for the LR3 modification — the N-terminal extension and the glutamic acid to arginine substitution at position 3 — was published by Francis and colleagues in 1992, demonstrating that the analog retained high IGF-1R binding affinity while exhibiting dramatically reduced IGFBP binding, resulting in enhanced in vitro and in vivo biological potency15. This work established IGF-1 LR3 as a valuable experimental reagent for studying IGF-1 biology without the confounding influence of binding protein dynamics.

Through the 1990s and 2000s, IGF-1 LR3 became widely adopted in cell biology and animal physiology research, particularly in studies of fetal growth, cardiac development, and metabolic regulation. Research groups including those at Oregon Health & Science University and the University of Colorado used continuous fetal sheep infusion models to characterize its growth-promoting and metabolic effects1,2,3. These studies revealed unexpected complexity in its pancreatic effects, including duration-dependent suppression of beta-cell insulin secretory function1,3.

More recently, IGF-1 LR3 has been incorporated into advanced tissue engineering applications, including controlled-release biomaterial scaffolds for peripheral nerve regeneration4, representing an emerging direction that leverages its neurotrophic properties through localized rather than systemic delivery. Human therapeutic development across indications including growth disorders, metabolic disease, and tissue regeneration represents an active area of ongoing investigation.

§07References